RxDoctor Payments Data

Amy Harmasch, MD

Internal Medicine · Moon Twp, PANPI 1588808802

Payments from drug & device makers

$1,166in general payments, 2019–2025

Across 67 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$397
  • AbbVie$240
  • GSK$157
  • Amgen$99
  • Lilly USA, LLC$48
  • Johnson & Johnson$47
  • plus $178 from 9 others

What the payments were for

  • Food & beverage$1,166100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,166 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$40,099
Medicare patients
128
Services billed
579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$75,274
EliquisApixaban77$69,475
JanuviaSitagliptin Phosphate27$40,621
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$33,143
XareltoRivaroxaban25$19,748
JardianceEmpagliflozin20$18,796
TradjentaLinagliptin18$14,926
Breo ElliptaFluticasone/Vilanterol28$14,179
FarxigaDapagliflozin Propanediol19$10,722
MyrbetriqMirabegron13$8,505
JanumetSitagliptin Phos/Metformin Hcl13$7,669
LinzessLinaclotide13$7,154
Fluticasone-SalmeterolFluticasone Propion/Salmeterol32$4,955
Atorvastatin Calcium505$4,773
SynthroidLevothyroxine Sodium63$3,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$397$75,27466 claims
PfizerEliquis$11$69,47577 claims
MerckJanuvia, Janumet$13$48,29040 claims
GSKTrelegy Ellipta, Breo Ellipta$157$47,32264 claims
Boehringer IngelheimJardiance, Tradjenta$25$33,72238 claims
Johnson & JohnsonXarelto$47$19,74825 claims
AstraZenecaFarxiga$42$10,72219 claims
AbbVieLinzess, Synthroid$240$10,45076 claims
Astellas Pharma US IncMyrbetriq$19$8,50513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Moon Twp

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →